Here are five things to know.
1. Radicava marks the first FDA-approved ALS treatment since riluzole hit the market in 1995, reports CNN.
2. The intravenous drug, developed by MT Pharma America, is administered daily in two-week treatment cycles.
3. The drug’s list price is $1,000 per infusion, which totals nearly $150,000 annually, according to CNN.
4. Clinical trials conducted in Japan show patients taking Radicava had slower disease progression than those taking a placebo.
5. Jersey City, N.J.-based MT Pharma expects Radicava to hit the market in August.
More articles on supply chain:
Blue Cross member plans spent 73% more on drugs in 2016 than 2010
Supply chain tip of the week: Using the right equipment suppliers at the right time
Forget clothes — this thrift shop sells medical equipment
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
